New Two-Pronged attack tested for Tough-to-Treat blood cancer
NCT ID NCT04586426
Summary
This study is testing a new combination of two drugs, talquetamab and teclistamab, for people with multiple myeloma that has come back or stopped responding to other treatments. The main goals are to find a safe and effective dose, check for side effects, and see how well the combination works to control the cancer. The study is for adults who have already tried several other standard therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alberta Health Services
Edmonton, Alberta, T6G 1Z2, Canada
-
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2, Canada
-
Asan Medical Center
Seoul, 05505, South Korea
-
Atrium Health
Charlotte, North Carolina, 28204, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Clinica Univ. de Navarra
Pamplona, 31008, Spain
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Hadassah Medical Center
Jerusalem, 91120, Israel
-
Hosp Clinic de Barcelona
Barcelona, 08036, Spain
-
Hosp Clinico Univ de Salamanca
Salamanca, 37007, Spain
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Hosp. Univ. Germans Trias I Pujol
Badalona, 08916, Spain
-
Hosp. Univ. Marques de Valdecilla
Santander, 39008, Spain
-
Inst. Cat. Doncologia-H Duran I Reynals
L'Hospitalet de Llobregat, 08908, Spain
-
Japanese Red Cross Medical Center
Shibuya City, 150-8935, Japan
-
Kanazawa University Hospital
Kanazawa, 920-8641, Japan
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
McGill University Health Centre
Montreal, Quebec, H4A 3J1, Canada
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Mount Sinai Medical Center
New York, New York, 10029, United States
-
Nagoya City University Hospital
Nagoya, 467 8602, Japan
-
Oregon Health And Science University
Portland, Oregon, 97239, United States
-
Osaka University Hospital
Osaka, 565-0871, Japan
-
Princess Margaret Cancer Centre University Health Network
Toronto, Ontario, M5G 1X6, Canada
-
Royal Perth Hospital
Perth, 6000, Australia
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital Yonsei University Health System
Seoul, 03722, South Korea
-
Sheba Medical Center
Ramat Gan, 52621, Israel
-
St Vincents Hospital Melbourne
Fitzroy, 3065, Australia
-
Tel Aviv Sourasky Medical Center
Tel Aviv, 64239, Israel
-
The Catholic University of Korea Seoul St Marys Hospital
Seoul, 06591, South Korea
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Tohoku University Hospital
Sendai, 980 8574, Japan
-
UNIV. HOSP. October 12
Madrid, 28041, Spain
-
University of Alabama at Birmingham, Comprehensive Cancer Center
Birmingham, Alabama, 35233, United States
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
-
Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
-
Washington University St. Louis School Medicine Siteman Cancer Center
St Louis, Missouri, 63108, United States
Conditions
Explore the condition pages connected to this study.